B7H3/CD3/PD-L1 targeted Tri-TCE (Shanghai Jiaotong University)

靶向B7H3/CD3/PD-L1三抗T细胞衔接器 (上海交通大学)

Report date: 2026/05/14 20:00:28

Base Information

Drug NameB7H3/CD3/PD-L1 targeted Tri-TCE (Shanghai Jiaotong University)

Drug Alias NameN/A

ClassificationBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionAnti-CD276Anti-CD3CD3 T-cell engagers +[4]

TargetsCD276 antigenT cell surface glycoprotein CD3Programmed death-ligand 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Jiaotong University

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiaotong University

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A